Glenmark Pharmaceuticals expands cardiometabolic portfolio with new Empagliflozin drug launch
Glenmark Pharmaceuticals Ltd. has introduced Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. Along with this, the company has launched ... Read More
AstraZeneca’s Forxiga wins approval in China for heart failure treatment
AstraZeneca has announced that its drug, Forxiga (dapagliflozin), has received approval from the Chinese National Medical Products Administration (NMPA) to reduce the risk of cardiovascular ... Read More
AstraZeneca’s Farxiga receives FDA breakthrough therapy designation for chronic kidney disease treatment
AstraZeneca's Farxiga (dapagliflozin), a leading drug in the management of chronic kidney disease (CKD), has been granted Breakthrough Therapy Designation (BTD) by the US Food ... Read More